Alaunos Therapeutics

TCRT

市值 US$668萬

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) stock is surging on Tuesday with a massive session volume of 191.48 million compared to the average volume of 826.167 thousand, according to Benzinga Pro data.

Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension

Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team BOSTON, Oct. 13, 2026 /PRNewswire/ -- Paragon Labs (together with related entities, "Paragon"), a biotechnology company focused on the discovery and development of differentiated biologics, today announced that members of the former senior leadership team of Apogee Therapeutics ("Apogee") have joined Paragon. The expanded leadership team will support Paragon-discovered assets through clinical development and help build new companies around promising therapeutic candidates, starting with Velaris Therapeutics, a biotechnology company focused on developing therapies for pulmonary hypertension and related cardiopulmonary diseases.

Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.

Shares of Alaunos Therapeutics Inc (NASDAQ:TCRT) rose sharply in pre-market trading following a Securities and Exchange Commission filing that showed the company approved and adopted its Second Amended and Restated By-Laws, effective immediately.

ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice A non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company's investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders.

FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate.

Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Ms. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built for Valion Bio's current phase of growth.

Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003.

Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, and improved liver biomarkers in preclinical studies.